KPIs & Operating Metrics(New)
Growth Metrics

Charles River Laboratories International (CRL) Non-Current Debt (2016 - 2025)

Charles River Laboratories International has reported Non-Current Debt over the past 17 years, most recently at $2.1 billion for Q4 2025.

  • Quarterly results put Non-Current Debt at $2.1 billion for Q4 2025, down 4.64% from a year ago — trailing twelve months through Dec 2025 was $2.1 billion (down 4.64% YoY), and the annual figure for FY2025 was $2.1 billion, down 4.64%.
  • Non-Current Debt for Q4 2025 was $2.1 billion at Charles River Laboratories International, down from $2.2 billion in the prior quarter.
  • Over the last five years, Non-Current Debt for CRL hit a ceiling of $3.0 billion in Q2 2022 and a floor of $2.1 billion in Q4 2025.
  • Median Non-Current Debt over the past 5 years was $2.7 billion (2023), compared with a mean of $2.6 billion.
  • Biggest five-year swings in Non-Current Debt: surged 38.04% in 2021 and later dropped 15.37% in 2024.
  • Charles River Laboratories International's Non-Current Debt stood at $2.7 billion in 2021, then rose by 1.65% to $2.7 billion in 2022, then decreased by 2.23% to $2.6 billion in 2023, then dropped by 15.37% to $2.2 billion in 2024, then dropped by 4.64% to $2.1 billion in 2025.
  • The last three reported values for Non-Current Debt were $2.1 billion (Q4 2025), $2.2 billion (Q3 2025), and $2.3 billion (Q2 2025) per Business Quant data.